The inhibition of sEH activity in order to prolong the bioactive half-life of endogenously generated EpFAs along with the administration of exogenous EpFA compounds are potential therapeutic strategies to protect cardiac mitochondria in failing DCM hearts. Here, EPHX2 is linked to familial dilated cardiomyopathy.